"A great step in treating cervical cancer": Patient and provider perceptions about cervical cancer therapeutic vaccines.
Where this comes from
- Record sourced from PubMed, PMID 38878586.
- Also identified by DOI 10.1016/j.pec.2024.108338 and PMC identifier 13340439.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This study explored patients and providers' perspectives on therapeutic vaccines for cervical cancer and assessed barriers and facilitators. Qualitative semi-structured in-depth interviews were conducted with patients who had cervical dysplasia, or a past or current cervical cancer diagnosis and providers who provided care to patients with cervical abnormalities or cervical cancer. Data were analyzed using thematic analysis in NVivo. A total of 28 in-depth interviews were conducted with patients (N = 15) and providers (N = 13). Participants in both groups expressed enthusiasm for the prospect of a therapeutic vaccine for cervical cancer and were encouraged by less invasive treatment opportunities. Perceived patient barriers included concerns about side effects, eligibility criteria, costs, transportation, and logistical obstacles. Providers echoed these concerns, highlighted additional structural barriers such as racism and limited availability of culturally sensitive educational aids, and underscored the need for provider training on this topic. Our results reinforce the need for future multi-level interventions discussing vaccine efficacy, durability, and safety, as well as addressing factors such as awareness, knowledge, and beliefs. Our findings can contribute to the development of provider and patient-centered tools that promote therapeutic vaccine acceptance.
Medical subject headings
- Uterine Cervical Neoplasms
- Qualitative Research
- Interviews as Topic
- Health Knowledge, Attitudes, Practice